Clinical Trial: A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT04846920) titled 'A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)' on April 7.

Brief Summary: The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating doses of belzutifan as second line positive (2L+) treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

Study Type: Interventional

Condition: Carcinoma, Renal Cell

Intervention: Drug: Belzutifan

40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.

Other Names: * MK-6482

* PT2977

Recruitment Status: Not Yet Recruiting

Sponsor: Merck Sharp & Dohme Co...